| Ytd | 158.90% | |
| 1y | 437.92% |
| Open | 80.00 | Prev Close | 80.89 | Low | 77.78 | High | 88.44 | Mkt Cap | 7.19B |
| Vol | 1.38M | Avg Vol | 1.88M | EPS | 0.14 | P/E | 577.79 | Forward P/E | 20.12 |
| Beta | 0.55 | Short Ratio | 4.76 | Inst. Own | 70.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 68.28 | 200-d Avg | 42.41 | 1yr Est | 74.25 |
LQDA News
Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands i
On July 13, 2026, Liquidia Corp (LQDA) shares experienced a notable decline of 8.7%, currently price
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help i
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitab
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? L
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad
B of A Securities analyst Jason Gerberry downgrades Liquidia (NASDAQ:LQDA) from Buy to Neutral an
Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monda
LQDA, FLXS and AGX screen as low-beta stocks with positive price moves, solid trading volume and com
BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take
MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharm
On June 08, 2026, Liquidia Corp (LQDA) shares rose 3.4% today, continuing a strong performance withi
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to
MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharm
Fragile Iran ceasefire keeps stocks volatile. Low-beta picks LQDA, CVX, OXY and VLO show recent gain
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concent
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return
Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? L
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announ
Liquidia Corp (LQDA) reported better-than-expected Q1 results, with earnings of 52 cents per share a
Wall Street analysts changed outlook on top names. For full view of analyst rating changes, see anal
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise
Needham analyst Serge Belanger maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price t
BTIG analyst Julian Harrison maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price tar
US stocks rise, Nasdaq up 0.3%. Liquidia Corp (LQDA) beats Q1 expectations, shares rise 15.7%. Other
Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.52 per share which beat the analyst consens
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise
Oppenheimer analyst Andreas Argyrides maintains Liquidia (NASDAQ:LQDA) with a Underperform and ra
Liquidia Corp (LQDA) reported mixed Q4 results, with earnings missing estimates but sales beating ex
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raise
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and ra
Liquidia (NASDAQ:LQDA) reported quarterly earnings of $0.15 per share which missed the analyst conse
